TELA Bio Inc.

Jun 06, 2019

TELA Bio® Announces One-Year Data from BRAVO Study of OviTex® Reinforced BioScaffolds for Ventral Hernia Repair

Apr 18, 2019

TELA Bio® Announces 510(k) Clearance for Restella(TM) Reconstructive BioScaffolds for Reconstructive Surgery

Apr 08, 2019

TELA Bio® to Present at 18th Annual Needham Healthcare Conference

Mar 11, 2019

TELA Bio® Announces Multiple Presentations at American Hernia Society Annual Meeting in Las Vegas

Jan 24, 2019

TELA Bio Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffolds

Jan 10, 2019

TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.

Jan 02, 2019

Nora Brennan Joins TELA Bio® as Chief Financial Officer

Sep 11, 2018

TELA Bio® Announces Publication of Case Series Evaluating OviTex® Reinforced BioScaffolds in Hiatal and Inguinal Hernia Repair

Jun 07, 2018

TELA Bio® Announces Initial Data from BRAVO Study of OviTex® Reinforced BioScaffolds for Ventral Hernia Repair

May 31, 2018

TELA Bio® Announces Plans to Launch OviTex® Reinforced BioScaffolds in Europe

Mar 12, 2018

TELA Bio Announces Results from Retrospective Study of OviTex Reinforced BioScaffolds for Abdominal Wall Reconstruction